224 related articles for article (PubMed ID: 36811414)
1. Ciltacabtagene autoleucel for the treatment of multiple myeloma.
Holstein SA
Drugs Today (Barc); 2023 Jan; 59(1):1-16. PubMed ID: 36811414
[TBL] [Abstract][Full Text] [Related]
2. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
3. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
Front Immunol; 2022; 13():991092. PubMed ID: 36119032
[TBL] [Abstract][Full Text] [Related]
4. Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
Martin TG; Madduri D; Pacaud L; Usmani SZ
Future Oncol; 2023 Nov; 19(34):2297-2311. PubMed ID: 37497629
[TBL] [Abstract][Full Text] [Related]
5. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
Mi JQ; Zhao W; Jing H; Fu W; Hu J; Chen L; Zhang Y; Yao D; Chen D; Schecter JM; Yang F; Tian X; Sun H; Zhuang SH; Ren J; Fan X; Jin J; Niu T; Chen SJ
J Clin Oncol; 2023 Feb; 41(6):1275-1284. PubMed ID: 36269898
[TBL] [Abstract][Full Text] [Related]
6. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Ri M; Suzuki K; Ishida T; Kuroda J; Tsukamoto T; Teshima T; Goto H; Jackson CC; Sun H; Pacaud L; Fujikawa E; Yeh TM; Hatayama T; Aida K; Sunagawa Y; Iida S
Cancer Sci; 2022 Dec; 113(12):4267-4276. PubMed ID: 36052883
[TBL] [Abstract][Full Text] [Related]
7. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Martin T; Usmani SZ; Berdeja JG; Agha M; Cohen AD; Hari P; Avigan D; Deol A; Htut M; Lesokhin A; Munshi NC; O'Donnell E; Stewart AK; Schecter JM; Goldberg JD; Jackson CC; Yeh TM; Banerjee A; Allred A; Zudaire E; Deraedt W; Olyslager Y; Zhou C; Pacaud L; Madduri D; Jakubowiak A; Lin Y; Jagannath S
J Clin Oncol; 2023 Feb; 41(6):1265-1274. PubMed ID: 35658469
[TBL] [Abstract][Full Text] [Related]
8. Cilta-cel OK'd for Multiple Myeloma.
Cancer Discov; 2022 May; 12(5):1176. PubMed ID: 35491644
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.
Martin T; Jackson CC; Pacaud L; Madduri D; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):22-27. PubMed ID: 36411210
[TBL] [Abstract][Full Text] [Related]
11. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
12. Sequence not salvage.
Sborov DW; Fortuna GG; Hayden PJ
Br J Haematol; 2024 May; 204(5):1590-1592. PubMed ID: 38563345
[TBL] [Abstract][Full Text] [Related]
13. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
Fang J; Zhou F
Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Costa LJ; Lin Y; Cornell RF; Martin T; Chhabra S; Usmani SZ; Jagannath S; Callander NS; Berdeja JG; Kang Y; Vij R; Godby KN; Malek E; Neppalli A; Liedtke M; Fiala M; Tian H; Valluri S; Marino J; Jackson CC; Banerjee A; Kansagra A; Schecter JM; Kumar S; Hari P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):326-335. PubMed ID: 34840088
[TBL] [Abstract][Full Text] [Related]
15. The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma.
Strassl I; Podar K
Expert Opin Drug Discov; 2024 Apr; 19(4):377-391. PubMed ID: 38369760
[TBL] [Abstract][Full Text] [Related]
16. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel J; Dhakal B; Yong K; Spencer A; Anguille S; Mateos MV; Fernández de Larrea C; Martínez-López J; Moreau P; Touzeau C; Leleu X; Avivi I; Cavo M; Ishida T; Kim SJ; Roeloffzen W; van de Donk NWCJ; Dytfeld D; Sidana S; Costa LJ; Oriol A; Popat R; Khan AM; Cohen YC; Ho PJ; Griffin J; Lendvai N; Lonardi C; Slaughter A; Schecter JM; Jackson CC; Connors K; Li K; Zudaire E; Chen D; Gilbert J; Yeh TM; Nagle S; Florendo E; Pacaud L; Patel N; Harrison SJ; Einsele H
N Engl J Med; 2023 Jul; 389(4):335-347. PubMed ID: 37272512
[TBL] [Abstract][Full Text] [Related]
17. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy.
Shen Y; Liu J; Wang B; Zhang Y; Xu Y; Wang X; Jia Y; Meng X; Wang X; Fan X; He A; Zhao W
Curr Res Transl Med; 2023; 71(2):103378. PubMed ID: 36720180
[TBL] [Abstract][Full Text] [Related]
18. Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
Jagannath S; Jackson CC; Schecter JM; Lendvai N; Sun H; Akram M; Patel N; Martin TG
Expert Opin Biol Ther; 2024 May; ():1-12. PubMed ID: 38738379
[TBL] [Abstract][Full Text] [Related]
19. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma.
Davis J; McGann M; Shockley A; Hashmi H
Expert Rev Hematol; 2022 Jun; 15(6):473-475. PubMed ID: 35603733
[No Abstract] [Full Text] [Related]
20. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
Htut M; Dhakal B; Cohen AD; Martin T; Berdeja JG; Usmani SZ; Agha M; Jackson CC; Madduri D; Deraedt W; Zudaire E; Yeh TM; Xu X; Pacaud L; Akram M; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):882-888. PubMed ID: 37716872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
